IBRX logo

ImmunityBio (IBRX)

Profile

Full Name

ImmunityBio, Inc.

Ticker Symbol

IBRX

Exchange

NASDAQ

Country

United States

IPO

July 28, 2015

Indexes

Not included

Employees

671

Key Details

Price

$2.69(-3.76%)

Last Dividend

-

TTM Dividend yield

-

Annual revenue

$14.74M(+2270.58% YoY)

Annual EPS

-$0.62(+46.09% YoY)

Next earnings date

Aug 12, 2025

Next ex-dividend date

N/A

Next split date

N/A

Quick Search

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
See Full Chart & Historical Data

Analyst ratings

Price

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price Performance

Price Range

Capitalization

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Market cap

Shares Outstanding

Technical Indicators

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Dividend

Income Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

EPS

Profit

Expenses

EBIT & EBITDA

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Liabilities

Debt

Equity & Capital

Cash Flow Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

CAPEX

Free Cash Flow

Profitability Ratios

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Margins

ROA & ROE

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PB Ratio

PS Ratio

Enterprise value

EV/EBITDA

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Leverage

Risk & Stability

Analyst ratings

Recent major analysts updates

Jun 4, 25 HC Wainwright & Co.
Buy
Jun 3, 25 D. Boral Capital
Buy
May 28, 25 D. Boral Capital
Buy
May 20, 25 Piper Sandler
Overweight
May 12, 25 HC Wainwright & Co.
Buy
May 12, 25 D. Boral Capital
Buy
Apr 28, 25 HC Wainwright & Co.
Buy
Apr 28, 25 D. Boral Capital
Buy
Apr 23, 25 D. Boral Capital
Buy
Apr 16, 25 HC Wainwright & Co.
Buy

Institutional Ownership

  • What is the ticker symbol for ImmunityBio?
  • Does ImmunityBio pay dividends?
  • What sector is ImmunityBio in?
  • What industry is ImmunityBio in?
  • What country is ImmunityBio based in?
  • When did ImmunityBio go public?
  • Is ImmunityBio in the S&P 500?
  • Is ImmunityBio in the NASDAQ 100?
  • Is ImmunityBio in the Dow Jones?
  • When was ImmunityBio's last earnings report?
  • When does ImmunityBio report earnings?
  • Should I buy ImmunityBio stock now?

What is the ticker symbol for ImmunityBio?

The ticker symbol for ImmunityBio is NASDAQ:IBRX

Does ImmunityBio pay dividends?

No, ImmunityBio does not pay dividends

What sector is ImmunityBio in?

ImmunityBio is in the Healthcare sector

What industry is ImmunityBio in?

ImmunityBio is in the Biotechnology industry

What country is ImmunityBio based in?

ImmunityBio is headquartered in United States

When did ImmunityBio go public?

ImmunityBio's initial public offering (IPO) was on July 28, 2015

Is ImmunityBio in the S&P 500?

No, ImmunityBio is not included in the S&P 500 index

Is ImmunityBio in the NASDAQ 100?

No, ImmunityBio is not included in the NASDAQ 100 index

Is ImmunityBio in the Dow Jones?

No, ImmunityBio is not included in the Dow Jones index

When was ImmunityBio's last earnings report?

ImmunityBio's most recent earnings report was on May 12, 2025

When does ImmunityBio report earnings?

The next expected earnings date for ImmunityBio is Aug 12, 2025

Should I buy ImmunityBio stock now?

As of today, analysts generally recommend a 'Strong buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions
On this page